TNDM241220P21000
- 0.00
- 0.000.00%
Tandem Diabetes Care Newsroom
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Tandem Diabetes Care Raised to Overweight From Equal-Weight by Morgan Stanley
Morgan Stanley Upgrades Tandem Diabetes Care(TNDM.US) to Buy Rating, Maintains Target Price $45
Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Express News | Tandem Diabetes Care Inc : Leerink Partners Cuts Target Price to $58 From $59
This Insider Has Just Sold Shares In Tandem Diabetes Care
Tandem Diabetes Care Announces Upcoming Conference Presentations
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
Assessing MedTech Impact From Potential China Tariffs
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $40 to $75
Here's What Analysts Are Forecasting For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) After Its Third-Quarter Results
Tandem Diabetes Care Is Maintained at Buy by Canaccord Genuity
Express News | Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $37
Tandem Diabetes Care Analyst Ratings
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $37 to $65
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
Express News | Tandem Diabetes Care Inc : Leerink Partners Cuts Target Price to $59 From $62